Loading
A phase 1/2 trial of ALE.P02 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by Alentis Therapeutics AG, now recruiting.
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT06747585 by Alentis Therapeutics AG, with 170 participants planned, started 2024-12-16 and due to reach its primary completion in 2028-02-15. Interventions recorded: ALE.P02.
Shares Alentis Therapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.